Curis Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Curis de 5.6% y 42.6% respectivamente, mientras que el BPA crecerá en un 30.8% al año.

Información clave

5.8%

Tasa de crecimiento de los beneficios

33.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	23.2%
Tasa de crecimiento de los ingresos	39.1%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	07 Mar 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Apr 03

Curis, Inc. (NASDAQ:CRIS) Stock Catapults 63% Though Its Price And Business Still Lag The Industry

Dec 26

Curis stock soars 34% as FDA lifts partial clinical hold on emavusertib's lymphoma study

Aug 18

Curis: Asymmetric Risk And Reward

Jul 17

Here's Why We're Not Too Worried About Curis' (NASDAQ:CRIS) Cash Burn Situation

Mar 28

Checking In On Curis

Dec 15

Companies Like Curis (NASDAQ:CRIS) Can Afford To Invest In Growth

Dec 04

We Think Curis (NASDAQ:CRIS) Can Afford To Drive Business Growth

Aug 29

Curis Inc.: Revisiting CA-4948 After Q2 Update

Aug 25

Curis, Inc. (NASDAQ:CRIS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$16.33

Mar 19

Announcing: Curis (NASDAQ:CRIS) Stock Soared An Exciting 625% In The Last Year

Feb 17

Curis Inc.: Understanding CA-4948 And IRAK-4 Inhibition

Dec 23

Curis prices equity offering at $5.75/share

Dec 09

Curis skyrockets 141% on encouraging CA-4948 data in leukemia

Dec 08

What You Need To Know About Curis, Inc.'s (NASDAQ:CRIS) Investor Composition

Dec 03

Curis, National Cancer Institute in development pact for anti-cancer agent

Nov 11

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:CRIS - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	11	-60	-53	-51	6
12/31/2025	9	-55	-49	-47	6
12/31/2024	9	-50	-47	-43	6
12/31/2023	10	-47	-38	-38	N/A
9/30/2023	10	-47	-41	-41	N/A
6/30/2023	10	-48	-46	-45	N/A
3/31/2023	10	-52	-50	-50	N/A
12/31/2022	10	-57	-55	-54	N/A
9/30/2022	10	-59	-51	-50	N/A
6/30/2022	11	-57	-47	-47	N/A
3/31/2022	11	-52	-41	-41	N/A
12/31/2021	11	-45	-38	-38	N/A
9/30/2021	11	-39	-35	-35	N/A
6/30/2021	10	-34	-32	-31	N/A
3/31/2021	10	-30	-30	-30	N/A
12/31/2020	11	-30	-26	-26	N/A
9/30/2020	11	-31	-26	-26	N/A
6/30/2020	11	-31	-27	-26	N/A
3/31/2020	11	-32	-28	-28	N/A
12/31/2019	10	-32	-26	-26	N/A
9/30/2019	9	-29	-26	-26	N/A
6/30/2019	9	-30	-27	-27	N/A
3/31/2019	10	-32	-27	-27	N/A
12/31/2018	10	-33	-30	-30	N/A
9/30/2018	11	-35	-33	-33	N/A
6/30/2018	11	-43	-41	-41	N/A
3/31/2018	10	-48	-43	-43	N/A
12/31/2017	10	-53	-49	-48	N/A
9/30/2017	9	-57	N/A	-50	N/A
6/30/2017	8	-70	N/A	-41	N/A
3/31/2017	8	-67	N/A	-43	N/A
12/31/2016	8	-60	N/A	-36	N/A
9/30/2016	7	-63	N/A	-37	N/A
6/30/2016	8	-40	N/A	-34	N/A
3/31/2016	8	-37	N/A	-30	N/A
12/31/2015	8	-59	N/A	-30	N/A
9/30/2015	8	-51	N/A	-24	N/A
6/30/2015	7	-51	N/A	-21	N/A
3/31/2015	10	-45	N/A	-19	N/A
12/31/2014	10	-19	N/A	-17	N/A
9/30/2014	9	-17	N/A	-18	N/A
6/30/2014	15	-14	N/A	-15	N/A
3/31/2014	15	-13	N/A	-11	N/A
12/31/2013	15	-12	N/A	-10	N/A
9/30/2013	15	-20	N/A	-17	N/A
6/30/2013	9	-22	N/A	-22	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que CRIS siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que CRIS siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que CRIS siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (42.6% al año) de CRIS crezcan más rápidamente que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (42.6% al año) de CRIS crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de CRIS se prevé que sea elevada dentro de 3 años.

Curis Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 22% to US$77.40

Consensus EPS estimates upgraded to US$6.06 loss

Consensus revenue estimates increase by 28%, EPS downgraded

Price target increased by 18% to US$180

Consensus EPS estimates fall by 12%

Price target increased to US$15.33

Recent updates

Curis, Inc. to Report Q1, 2024 Results on May 07, 2024

Price target decreased by 22% to US$77.40

Curis, Inc., Annual General Meeting, May 21, 2024

Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Consensus EPS estimates upgraded to US$6.06 loss

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 28%, EPS downgraded

Full year 2023 earnings: EPS and revenues miss analyst expectations

Curis, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Curis, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Curis, Inc. (NASDAQ:CRIS) Stock Catapults 63% Though Its Price And Business Still Lag The Industry

Curis, Inc. Announces Initial Combination Study Data from Its Take Aim Lymphoma Study

New major risk - Share price stability

Price target increased by 18% to US$180

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

We're A Little Worried About Curis' (NASDAQ:CRIS) Cash Burn Rate

Curis, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Share price stability

We're Hopeful That Curis (NASDAQ:CRIS) Will Use Its Cash Wisely

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Curis, Inc. to Report Q2, 2023 Results on Aug 03, 2023

U.S. Food and Drug Administration Removes Partial Clinical Hold on Curis, Inc.'s TakeAim Leukemia Study RP2D Established At 300 Mg BID

Consensus EPS estimates fall by 12%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?

Curis, Inc. Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS

Price target increased to US$15.33

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$12.25

Curis, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Curis Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price

Curis, Inc. Elects Anne E. Borgman as Class I Director

Curis, Inc. Announces Resignation of Lori A. Kunkel, M.D. from the Board of Directors, Effective September 30, 2022

Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Curis, Inc. Announces That the U.S. Food and Drug Administration (FDA) Has Notified Curis That It May Resume Enrollment of Additional Patients in the Monotherapy Phase of the TakeAim Leukemia Study

FDA Lifts Partial Clinical Hold on the Takeaim Lymphoma Study of Emavusertib of Curis, Inc

Curis stock soars 34% as FDA lifts partial clinical hold on emavusertib's lymphoma study

Price target increased to US$17.67

Curis, Inc. Appoints Diantha Duvall as Chief Financial Officer, Treasurer, Assistant Secretary, Principal Financial Officer and Principal Accounting Officer of the Company Effective as of August 5, 2022

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Curis, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Curis: Asymmetric Risk And Reward

Curis, Inc. Announces Resignation of William Steinkrauss as Chief Administrative Officer, Effective from August 5, 2022

Curis, Inc.(NasdaqGM:CRIS) dropped from Russell 3000E Growth Index

Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)

Consensus EPS estimates fall by 14%

Price target increased to US$15.75

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$14.20

Curis, Inc., Annual General Meeting, May 26, 2022

Curis, Inc. Announces FDA Partial Clinical Hold for on the Company’s Takeaim Lymphoma Phase 1/2 Study

Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)

Here's Why We're Not Too Worried About Curis' (NASDAQ:CRIS) Cash Burn Situation

Curis, Inc. Announces Gastroenterology Publication of Encouraging Preclinical Data of Emavusertib in Pancreatic Cancers

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations

Curis, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory AML and MDS; and Initial Clinical Data from Phase 1 Study of CI-8993 in Patients with Relapsed or Refractory Solid Tumors

Checking In On Curis

Companies Like Curis (NASDAQ:CRIS) Can Afford To Invest In Growth

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.11 loss in 3Q 2020)

Insufficient new directors

Insufficient new directors

We Think Curis (NASDAQ:CRIS) Can Afford To Drive Business Growth

Curis Inc.: Revisiting CA-4948 After Q2 Update

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.17 loss in 2Q 2020)

Curis Announces Positive Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes